Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
$64.97
$64.81
$8.33
$65.00
$4.46B0.971.92 million shs2 shs
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
$0.07
$0.01
$0.01
$726K1.632.58 million shs2.48 million shs
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
$2.68
-13.8%
$1.33
$0.89
$24.00
$13.61M2.161.59 million shs2.07 million shs
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
$0.07
$0.06
$0.06
$3.23
N/A0.98974,985 shsN/A
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
$1.38
-4.2%
$1.17
$0.85
$4.30
$21.90M1.78219,834 shs390,870 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
0.00%0.00%0.00%0.00%0.00%
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
-13.83%+120.58%+111.02%+92.81%-87.88%
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
0.00%0.00%0.00%0.00%-96.78%
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
-4.17%0.00%+43.74%-11.25%-28.50%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
1.2295 of 5 stars
0.05.00.00.02.80.00.6
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
2.3155 of 5 stars
3.53.00.00.00.61.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
0.00
N/AN/AN/A
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
0.00
N/AN/AN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
0.00
N/AN/AN/A
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
0.00
N/AN/AN/A
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
3.00
Buy$6.25352.90% Upside

Current Analyst Ratings Breakdown

Latest INFI, MBIO, VYNE, ALPN, and TFFP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/25/2025
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.75 ➝ $4.50
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
$56.52M78.85N/AN/A$4.85 per share13.40
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
$2.59M0.00N/AN/A($0.21) per share0.00
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/AN/AN/AN/A($2.11) per shareN/A
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
$730K0.40N/AN/A$4.04 per share0.02
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
$500K41.98N/AN/A$3.53 per share0.39
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
-$32.18M-$0.64N/AN/AN/A-65.17%-14.86%-11.82%N/A
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
-$44.37M-$0.46N/AN/AN/A-1,593.93%N/A-113.02%N/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
-$15.75M-$78.00N/AN/AN/AN/AN/A-80.79%8/12/2025 (Estimated)
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
-$21.24M-$6.44N/AN/AN/AN/AN/AN/A
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
-$39.83M-$0.99N/AN/AN/A-6,974.55%-71.89%-58.94%8/13/2025 (Estimated)

Latest INFI, MBIO, VYNE, ALPN, and TFFP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/A-$0.05N/A-$0.05N/AN/A
5/8/2025Q1 2025
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
-$0.29-$0.20+$0.09-$0.20$0.05 million$0.20 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
N/AN/AN/AN/AN/A
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
N/AN/AN/AN/AN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/AN/AN/AN/AN/A
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
N/AN/AN/AN/AN/A
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
N/A
9.56
9.56
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
N/A
1.65
1.65
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/A
1.34
1.34
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
N/AN/AN/A
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
N/A
4.47
4.47
CompanyEmployeesShares OutstandingFree FloatOptionable
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
14268.60 million39.58 millionOptionable
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
3090.76 million81.86 millionOptionable
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
1004.38 million4.37 millionNot Optionable
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
194.44 million4.24 millionOptionable
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
3015.21 million14.48 millionNot Optionable

Recent News About These Companies

VYNE Therapeutics Provides Update on VYN202 Program

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alpine Immune Sciences stock logo

Alpine Immune Sciences NASDAQ:ALPN

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.

Infinity Pharmaceuticals stock logo

Infinity Pharmaceuticals NASDAQ:INFI

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.

Mustang Bio stock logo

Mustang Bio NASDAQ:MBIO

$2.68 -0.43 (-13.83%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$2.64 -0.05 (-1.68%)
As of 07:40 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

TFF Pharmaceuticals stock logo

TFF Pharmaceuticals NASDAQ:TFFP

$0.06 0.00 (0.00%)
As of 04/10/2025

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.

VYNE Therapeutics stock logo

VYNE Therapeutics NASDAQ:VYNE

$1.38 -0.06 (-4.17%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$1.40 +0.02 (+1.59%)
As of 07:41 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.